X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/01/03/2803216/0/en/Noema-Pharma-to-Present-at-Two-Upcoming-Conferences.html
https://www.globenewswire.com/news-release/2023/06/21/2691841/0/en/Noema-Pharma-Appoints-Ilise-Lombardo-M-D-as-Chief-Executive-Officer.html
https://www.globenewswire.com/news-release/2023/05/09/2664227/0/en/Noema-Pharma-to-Present-at-BioEquity-Europe-2023.html
https://www.globenewswire.com/news-release/2023/03/07/2621688/0/en/Noema-Pharma-Raises-CHF-103-Million-USD-112-Million-in-Series-B-Financing-Round-Led-by-Forbion-and-Jeito-Capital.html
https://www.globenewswire.com//news-release/2023/01/05/2584060/0/en/UPDATE-Noema-Pharma-to-Attend-and-Present-at-41st-Annual-J-P-Morgan-Healthcare-Conference-in-San-Francisco.html
https://www.globenewswire.com/news-release/2022/10/18/2536323/0/en/Noema-Pharma-Receives-FDA-Fast-Track-Designation-for-basimglurant-NOE-101-in-Trigeminal-Neuralgia.html
https://www.globenewswire.com/news-release/2022/09/06/2510365/0/en/Noema-Pharma-Announces-Completion-of-Enrollment-in-the-Trigeminal-Neuralgia-Electronic-Diary-TNED-Validation-Study.html
https://www.globenewswire.com/news-release/2022/08/04/2492274/0/en/Noema-Pharma-Announces-Recruitment-of-First-Patient-in-Orpheus-Phase-2b-Study-of-PDE10A-Inhibitor-gemlapodect-in-Adults-with-Childhood-Onset-Fluency-Disorder.html
https://www.globenewswire.com/news-release/2022/06/27/2469443/0/en/Noema-Pharma-Announces-FDA-Investigational-New-Drug-IND-Authorization-for-Orpheus-Phase-2b-Study-of-PDE10A-Inhibitor-Gemlapodect-NOE-105-in-Childhood-Onset-Fluency-Disorder.html
Market Place
Share 
